ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Galenica, a midsized Swiss drugmaker, has agreed to acquire the California biotech firm Relypsa for $1.5 billion in cash. Founded in 2007, Relypsa develops polymeric medicines for patients with conditions that can be treated in the gastrointestinal tract. FDA approved its first product, a treatment for elevated blood potassium levels, in October 2015. The drug, Veltassa, is based on a fluorinated polymer manufactured by the fine chemicals companies Saltigo and Patheon.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X